other material
confidence high
sentiment positive
materiality 0.70
Denali Therapeutics sells rare pediatric disease PRV for $195M
Denali Therapeutics Inc.
- Gross proceeds of $195M from sale of PRV to a large pharmaceutical company.
- PRV received from FDA approval of AVLAYA (tividenofusp alfa) for Hunter syndrome in March 2026.
- Sale closed on July 27, 2026, per asset purchase agreement dated June 12, 2026.
- Proceeds provide significant cash infusion; no other terms disclosed.